Skip to main content
SpringerLink
Log in

Background and Rationale for Radiotherapy in Advanced-Stage Hodgkin Lymphoma

  • Chapter
  • First Online:
Radiotherapy for Hodgkin Lymphoma

  • 968 Accesses

Abstract

The outcome of patients with Hodgkin lymphoma (HL) has improved dramatically because of the improvement of both chemotherapy and radiotherapy.

The treatment of patients with advanced HL has changed tremendously from extensive radiation as the one and only treatment option to limited irradiation in addition to chemotherapy or even to chemotherapy without any additional radiotherapy.

For patients with advanced-stage HL, powerful chemotherapy is indicated, in case of a partial remission after chemotherapy, followed by radiotherapy to residual abnormalities using only a small margin. In the future, treatment will be tailored to individual patients based on prognostic factors, possibly including biological markers, and accurate evaluation of response to treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Aleman BM, Raemaekers JM, Tirelli U et al (2003a) Involved-field radiotherapy for advanced Hodgkin’s lymphoma. N Engl J Med 348:2396–2406

    Article  PubMed  Google Scholar 

  • Aleman BM, Raemaekers JM, Tomisic R et al (2007) Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys 67:19–30

    Article  PubMed  Google Scholar 

  • Aleman BM, van den Belt-Dusebout AW, Klokman WJ et al (2003b) Long-term cause-specific mortality of patients treated for Hodgkin’s disease. J Clin Oncol 21:3431–3439

    Article  PubMed  Google Scholar 

  • Bagshaw MA, Kaplan HS, Rosenberg SA (1968) Extended-field radiation therapy in Hodgkin’s disease. A progress report. Radiol Clin N Am 6:63–70

    PubMed  CAS  Google Scholar 

  • Bartlett NL, Rosenberg SA, Hoppe RT et al (1995) Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin’s disease: a preliminary report. J Clin Oncol 13:1080–1088

    PubMed  CAS  Google Scholar 

  • Bonadonna G, Zucali R, Monfardini S et al (1975) Combination chemotherapy of Hodgkin’s disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 36:252–259

    Article  PubMed  CAS  Google Scholar 

  • Canellos GP, Anderson JR, Propert KJ et al (1992) Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327:1478–1484

    Article  PubMed  CAS  Google Scholar 

  • Cheson BD, Pfistner B, Juweid ME et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579–586

    Article  PubMed  Google Scholar 

  • Desser RK, Golomb HM, Ultmann JE et al (1977) Prognostic classification of Hodgkin disease in pathologic stage III, based on anatomic considerations. Blood 49:883–893

    PubMed  CAS  Google Scholar 

  • Diehl V, Franklin J, Pfreundschuh M et al (2003) Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. N Engl J Med 348:2386–2395

    Article  PubMed  CAS  Google Scholar 

  • Diehl V, Thomas RK, Re D (2004) Part II: Hodgkin’s lymphoma–diagnosis and treatment. Lancet Oncol 5:19–26

    Article  PubMed  CAS  Google Scholar 

  • Duggan DB, Petroni GR, Johnson JL et al (2003) Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin’s disease: report of an intergroup trial. J Clin Oncol 21:607–614

    Article  PubMed  CAS  Google Scholar 

  • Eich HT, Gossmann A, Engert A et al (2007) A Contribution to solve the problem of the need for consolidative radiotherapy after intensive chemotherapy in advanced stages of Hodgkin’s lymphoma–analysis of a quality control program initiated by the radiotherapy reference center of the German Hodgkin Study Group (GHSG). Int J Radiat Oncol Biol Phys 69:1187–1192

    Article  PubMed  Google Scholar 

  • Fabian CJ, Mansfield CM, Dahlberg S et al (1994) Low-dose involved field radiation after chemotherapy in advanced Hodgkin disease. A Southwest Oncology Group randomized study. Ann Intern Med 120:903–912

    PubMed  CAS  Google Scholar 

  • Ferme C, Mounier N, Casasnovas O et al (2006) Long-term results and competing risk analysis of the H89 trial in patients with advanced-stage Hodgkin lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte (GELA). Blood 107:4636–4642

    Article  PubMed  CAS  Google Scholar 

  • Ferme C, Mounier N, Divine M et al (2002) Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin’s disease in relapse or failure after initial chemotherapy: results of the Groupe d’Etudes des Lymphomes de l’Adulte H89 Trial. J Clin Oncol 20:467–475

    Article  PubMed  CAS  Google Scholar 

  • Ferme C, Sebban C, Hennequin C et al (2000) Comparison of chemotherapy to radiotherapy as consolidation of complete or good partial response after six cycles of chemotherapy for patients with advanced Hodgkin’s disease: results of the groupe d’etudes des lymphomes de l’Adulte H89 trial. Blood 95:2246–2252

    PubMed  CAS  Google Scholar 

  • Girinsky T, van der Maazen R, Specht L et al (2006) Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol 79:270–277

    Article  PubMed  Google Scholar 

  • Gobbi PG, Levis A, Chisesi T et al (2005) ABVD versus modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin’s lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol 23:9198–9207

    Article  PubMed  CAS  Google Scholar 

  • Hancock SL, Hoppe RT (1996) Long-term complications of treatment and causes of mortality after Hodgkin’s disease. Semin Radiat Oncol 6:225–242

    Article  PubMed  Google Scholar 

  • Hasenclever D, Diehl V (1998) A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med 339:1506–1514

    Article  PubMed  CAS  Google Scholar 

  • Henry-Amar M, Aeppli DM, Anderson J et al (1990a) Workshop statistical report. In: Somers R, Henry-Amar M, Meerwaldt JH et al (eds) Treatment strategy in Hodgkin’s disease. INSERM/John Libbey Eurotext, London

    Google Scholar 

  • Henry-Amar M, Hayat M, Meerwaldt JH et al (1990b) Causes of death after therapy for early stage Hodgkin’s disease entered on EORTC protocols. EORTC Lymphoma Cooperative Group. Int J Radiat Oncol Biol Phys 19:1155–1157

    Article  PubMed  CAS  Google Scholar 

  • Hoppe RT, Portlock CS, Glatstein E et al (1979) Alternating chemotherapy and irradiation in the treatment of advanced Hodgkin’s disease. Cancer 43:472–481

    Article  PubMed  CAS  Google Scholar 

  • Hoppe RT, Rosenberg SA, Kaplan HS et al (1980) Prognostic factors in pathological stage IIIA Hodgkin’s disease. Cancer 46:1240–1246

    Article  PubMed  CAS  Google Scholar 

  • Horning SJ, Ang PT, Hoppe RT et al (1992) The Stanford experience with combined procarbazine, Alkeran and vinblastine (PAVe) and radiotherapy for locally extensive and advanced stage Hodgkin’s disease. Ann Oncol 3:747–754

    PubMed  CAS  Google Scholar 

  • Horning SJ, Williams J, Bartlett NL et al (2000) Assessment of the Stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin’s disease: Eastern Cooperative Oncology Group pilot study E1492. J Clin Oncol 18:972–980

    PubMed  CAS  Google Scholar 

  • Kaplan HS, Rosenberg SA (1966) Extended-field radical radiotherapy in advanced Hodgkin’s disease: short-term results of 2 randomized clinical trials. Cancer Res 26:1268–1276

    PubMed  CAS  Google Scholar 

  • Klimm B, Eich H, Haverkamp H et al (2007) Poorer outcome of elderly patients treated with extended-field radiotherapy compared with involved-field radiotherapy after chemotherapy for Hodgkin’s lymphoma: an analysis from the German Hodgkin Study Group. Ann Oncol 18:357–363

    Article  PubMed  CAS  Google Scholar 

  • Kobe C, Dietlein M, Franklin J et al (2008) Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood 112:3989–3994

    Article  PubMed  CAS  Google Scholar 

  • Kremer LC, van Dalen EC, Offringa M et al (2001) Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. J Clin Oncol 19:191–196

    PubMed  CAS  Google Scholar 

  • Loeffler M, Brosteanu O, Hasenclever D et al (1998) Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin’s disease. International Database on Hodgkin’s Disease Overview Study Group. J Clin Oncol 16:818–829

    PubMed  CAS  Google Scholar 

  • Moser EC, Noordijk EM, van Leeuwen FE et al (2006) Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma. Blood 107:2912–2919

    Article  PubMed  CAS  Google Scholar 

  • Radford JA, Rohatiner AZ, Ryder WD et al (2002) ChlVPP/EVA hybrid versus the weekly VAPEC-B regimen for previously untreated Hodgkin’s disease. J Clin Oncol 20:2988–2994

    Article  PubMed  CAS  Google Scholar 

  • Rosenberg SA, Kaplan HS (1985) The evolution and summary results of the Stanford randomized clinical trials of the management of Hodgkin’s disease: 1962-1984. Int J Radiat Oncol Biol Phys 11:5–22

    Article  PubMed  CAS  Google Scholar 

  • Shahidi M, Kamangari N, Ashley S et al (2006) Site of relapse after chemotherapy alone for stage I and II Hodgkin’s disease. Radiother Oncol 78:1–5

    Article  PubMed  Google Scholar 

  • Sureda A, Arranz R, Iriondo A et al (2001) Autologous stem-cell transplantation for Hodgkin’s disease: results and prognostic factors in 494 patients from the Grupo Espanol de Linfomas/Transplante Autologo de Medula Osea Spanish Cooperative Group. J Clin Oncol 19:1395–1404

    PubMed  CAS  Google Scholar 

  • Swerdlow AJ, Barber JA, Hudson GV et al (2000) Risk of second malignancy after Hodgkin’s disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol 18:498–509

    PubMed  CAS  Google Scholar 

  • Swerdlow AJ, Higgins CD, Smith P et al (2007) Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst 99:206–214

    Article  PubMed  Google Scholar 

  • Travis LB, Hill DA, Dores GM et al (2003) Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA 290:465–475

    Article  PubMed  Google Scholar 

  • van Leeuwen FE, Klokman WJ, Stovall M et al (2003) Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin’s disease. J Natl Cancer Inst 95:971–980

    Article  PubMed  Google Scholar 

  • van Leeuwen FE, Klokman WJ, Veer MB et al (2000) Long-term risk of second malignancy in survivors of Hodgkin’s disease treated during adolescence or young adulthood. J Clin Oncol 18:487–497

    PubMed  Google Scholar 

  • Young RC, Canellos GP, Chabner BA et al (1978) Patterns of relapse in advanced Hodgkin’s disease treated with combination chemotherapy. Cancer 42:1001–1007

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Stanford University, 875 Blake Wilbur Dr, Rm CCG224, Stanford, CA, 94305-5847, USA

    Richard Hoppe

  2. Department of Radiotherapy, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066 CX, The Netherlands

    Berthe Aleman

Authors
  1. Richard Hoppe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Berthe Aleman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Richard Hoppe .

Editor information

Editors and Affiliations

  1. Rigshospitalet, Dept. Oncology 3994, Koebenhavns Universitet, Blegdamsvej 9, Koebenhavn, 2100, Denmark

    Lena Specht

  2. Dept. Radiation Oncology, Memorial Sloan-Kettering Cancer Center, York Ave. 1275, New York, 10021, New York, USA

    Joachim Yahalom

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Berlin Heidelberg

About this chapter

Cite this chapter

Hoppe, R., Aleman, B. (2011). Background and Rationale for Radiotherapy in Advanced-Stage Hodgkin Lymphoma. In: Specht, L., Yahalom, J. (eds) Radiotherapy for Hodgkin Lymphoma. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-78944-4_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-78944-4_3

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-78455-5

  • Online ISBN: 978-3-540-78944-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation